| Breast cancer |
oncogenic/ tumor suppressive |
First identified as an H3K4 demethylase, a specific DNA-binding protein and a potential downstream target of HER2/ERBB2. KDM5B promoted cell proliferation though transcriptional repressing tumor suppressor genes, luminal-high genes, specific microRNAs and contributed to poor survival. In some certain types of breast cancer like ER- or TNBC, KDM5B served as an anti-oncogenic player. |
1,18,24,56-65 |
| Melanoma |
oncogenic/ tumor suppressive |
High KDM5B expression was correlated with lower survival. KDM5B exerted tumor suppressive functions through many ways. KDM5B may have a dual role over time, first anti-proliferative but long-term tumor maintaining. Inhibition of mitochondrial respiratory chain decreased the slow-cycling KDM5B high cells and overcame drug-resistant. |
36,63,66-71 |
| Bladder cancer |
oncogenic |
KDM5B depletion resulted in suppression of cell growth through co-regulation of the E2F/RB1 pathway. KDM5B repressed connexin 26's expression. |
72,73 |
| Lung cancer |
oncogenic |
KDM5B depletion resulted in suppression of cell growth through co-regulation of the E2F/RB1 pathway. KDM5B stimulated cell proliferation and invasion by affecting p53. |
72,74 |
| Gastric cancer |
oncogenic |
KDM5B promoted cell growth and metastasis by regulating Akt pathway. |
75 |
| Prostate cancer |
oncogenic |
KDM5B promoted androgen receptor target genes’ activation. It was negative regulated by miR-29a and its protein stability was modulated by SKP2. |
8,9,31,76 |
| Hepatocellular carcinoma |
oncogenic |
KDM5B expression was related well with tumor size, TNM stage, edmondson grade, and poor prognosis. |
77 |
| Neuroblastoma |
oncogenic |
KDM5B promoted tumor sphere formation and invasion and resisted cisplatin treatment. |
78 |
| Oral squamous cancer |
oncogenic |
Silencing KDM5B inhibited CSC activity, migration and invasion, potentiated the effect of radiation therapy. |
79 |
| Head and neck squamous cell carcinoma |
oncogenic |
KDM5B knockdown resulted in G1 arrest and early apoptosis by suppressing Bcl-2 family members. |
80 |
| Esophageal squamous cell carcinoma |
oncogenic |
KDM5B knockdown suppressed cancer cell growth, invasion, sphere formation and tumorigenicity. A correlation was observed between KDM5B nuclear expression level and histological grade. |
81,82 |
| Colorectal cancer |
oncogenic |
KDM5B depletion induced cellular senescence and suppressed cancer cell growth. |
35 |
| Epithelial ovarian cancer |
oncogenic |
High KDM5B expression was associated with low PFS, OS and chemotherapy resistance. |
83 |
| cervical cancer |
oncogenic |
High KDM5B expression was associated with cancer cell growth and tumorigenicity. |
72 |
| renal cell carcinoma |
oncogenic |
High KDM5B expression was associated with cancer cell growth and tumorigenicity. |
72 |
| Diffuse large B-cell lymphoma |
oncogenic |
High frequency of KDM5B CT gene expression appeared to be a good candidate for therapy. |
84 |
| Leukemia |
oncogenic |
Depletion of KDM5B resulted in losing cell viability and inducing apoptosis. |
85 |
